Skipping the Advisory Committee, but Getting the Advice
The RPM Report November 2011, Vol. 7, No. 10
Feature Articles / Word Count: 1801 / Article # 2011500139
Executive Summary
Pfizer’s Xalkori sailed through FDA without an advisory committee review. But FDA did consult with two outside advisors--including the Oncology Committee Chair--along the way.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.